There are more than 33 million people living with HIV/AIDS worldwide, according to the World Health Organisation, the majority of them in sub-Saharan Africa. At present, over three million people living with HIV/AIDS in the developing world receive antiretroviral therapy (ART) and in addition, seven million people who are in need of treatment, are still waiting for access. MSF began supporting people living with HIV in the 1990s and started antiretroviral treatment programmes in Cameroon, Thailand, and South Africa in 2000.
MSF now operates HIV/AIDS programmes in more than 30 countries and provides antiretroviral (ARV) treatment to more than 140,000
HIV-positive adult and child patients. This global scope of its operations means MSF is able to observe varied challenges in its treatment of HIV/AIDS in different contexts, affording MSF a broad insight into how to fight the disease.

Slideshow

LATEST EVENTS

Press Conference

Optimise now, or pay later…
Sub-optimal treatment threatens long-term survival of people living with HIV/AIDS

Cape Town, 20 July 2009 – The stagnation of HIV/AIDS funding and the high cost of new medicines put the lives of thousands of poor patients at risk. Patients needing new drug regimens will return to AIDS death row, warns medical humanitarian organisation Médecins Sans Frontières (MSF) at the 2009 International AIDS Society conference. While the lack of access to antiretroviral treatment for seven million people remains unaddressed, inadequate financing now further threatens treatment scale-up.
Read more...

Satellite Meetings

Drug resistant tuberculosis and HIV infection: What can we do NOW?

Over the past decade, due to global public pressure, an estimated three million people have been initiated on antiretroviral treatment (ART). While this represents considerable progress, seven million people are still waiting for first line ART. At the same time, a growing number of people who have been able to access ART are starting to reach the limits of their current treatment. This satellite will explore what it will take to ensure long-term survival on ART in resource-limited settings, as well as the major threats towards realising this goal.
Click to see the programme leaflet

THE EMERGENCY IS NOT OVER: Access to Treatment and the Challenges of Long-Term Survival on Antiretrovirals

Over the past decade, due to globalpublic pressure, an estimated three million people have been initiated on antiretroviral treatment (ART). While this represents considerable progress, seven million people are still waiting for first line ART. At the same time, a growing number of people who have been able to access ART are starting to reach the limits of their current treatment. This satellite will explore what it will take to ensure long-term survival on ART in resource-limited settings, as well as the major threats towards realising this goal.
Click to see the programme leaflet
Click here to see presentations

Disruptions in HIV drug supplies and funding endanger patient lives

Cape Town, 17 July 2009 - Disruptions in the supply of anti-retroviral (ARV) drugs and other essential medical items in at least six African countries are putting HIV patients’ lives at risk. Funding gaps and supply management problems have led to the delay, suspension, or risk of suspension of the supply of life-saving HIV drugs.
Read more...